Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate. Issue 4 (19th March 2019)
- Record Type:
- Journal Article
- Title:
- Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate. Issue 4 (19th March 2019)
- Main Title:
- Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate
- Authors:
- O'Farrell, Alice C.
Miller, Ian S.
Evans, Rhys
Alamanou, Marina
Cary, Maurice
Mallya Udupi, Girish
Lafferty, Adam
Monsefi, Naser
Cremona, Mattia
Prehn, Jochen H. M.
Verheul, Henk M.
Gallagher, William M.
Gehrmann, Mathias
Byrne, Annette T. - Abstract:
- Abstract : Purpose: The tyrosine kinase inhibitor (TKI) sunitinib is a multi‐targeted agent approved across multiple cancer indications. Nevertheless, since approval, data has emerged to describe a worrisome side effect profile including hypertension, hand‐foot syndrome, fatigue, diarrhea, mucositis, proteinuria, and (rarely) congestive heart failure. It has been hypothesized that the observed multi‐parameter toxicity profile is related to "on‐target" kinase inhibition in "off‐target" tissues. Experimental Design: To interrogate off‐target effects in pre‐clinical studies, a reverse phase protein array (RPPA) approach is employed. Mice are treated with sunitinib (40 mg kg −1 ) for 4 weeks, following which critical organs are removed. The Zeptosens RPPA platform is employed for protein expression analysis. Results: Differentially expressed proteins associated with damage and/or stress are found in the majority of organs from treated animals. Proteins differentially expressed in the heart are associated with myocardial hypertrophy, ischaemia/reperfusion, and hypoxia. However, hypertrophy is not evidenced on histology. Mild proteinuria is observed; however, no changes in renal glomerular structure are visible via electron microscopy. In skin, proteins associated with cutaneous inflammation, keratinocyte hyper‐proliferation, and increased inflammatory response are differentially expressed. Conclusions and Clinical Relevance: It is posited that pre‐clinical implementation of aAbstract : Purpose: The tyrosine kinase inhibitor (TKI) sunitinib is a multi‐targeted agent approved across multiple cancer indications. Nevertheless, since approval, data has emerged to describe a worrisome side effect profile including hypertension, hand‐foot syndrome, fatigue, diarrhea, mucositis, proteinuria, and (rarely) congestive heart failure. It has been hypothesized that the observed multi‐parameter toxicity profile is related to "on‐target" kinase inhibition in "off‐target" tissues. Experimental Design: To interrogate off‐target effects in pre‐clinical studies, a reverse phase protein array (RPPA) approach is employed. Mice are treated with sunitinib (40 mg kg −1 ) for 4 weeks, following which critical organs are removed. The Zeptosens RPPA platform is employed for protein expression analysis. Results: Differentially expressed proteins associated with damage and/or stress are found in the majority of organs from treated animals. Proteins differentially expressed in the heart are associated with myocardial hypertrophy, ischaemia/reperfusion, and hypoxia. However, hypertrophy is not evidenced on histology. Mild proteinuria is observed; however, no changes in renal glomerular structure are visible via electron microscopy. In skin, proteins associated with cutaneous inflammation, keratinocyte hyper‐proliferation, and increased inflammatory response are differentially expressed. Conclusions and Clinical Relevance: It is posited that pre‐clinical implementation of a combined histopathological/RPPA approach provides a sensitive method to mechanistically elucidate the early manifestation of TKI on‐target/organ off‐target toxicities. … (more)
- Is Part Of:
- Proteomics. Volume 13:Issue 4(2019)
- Journal:
- Proteomics
- Issue:
- Volume 13:Issue 4(2019)
- Issue Display:
- Volume 13, Issue 4 (2019)
- Year:
- 2019
- Volume:
- 13
- Issue:
- 4
- Issue Sort Value:
- 2019-0013-0004-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2019-03-19
- Subjects:
- off‐target toxicity -- preclinical models -- reverse phase protein arrays -- sunitinib -- tyrosine kinase inhibitors
Proteomics -- Periodicals
572.605 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1862-8354 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/prca.201800159 ↗
- Languages:
- English
- ISSNs:
- 1862-8346
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6936.178500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14150.xml